Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment Hitachi, Ltd. Mar 25, 2022 11:48 HKT/SGT Read More
Joint Research Shows that DENSO's Microalga, Coccomyxa sp. KJ Has Virucidal Effect against COVID-19 Denso Mar 24, 2022 10:05 HKT/SGT Read More
エーザイとバイオジェン、抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会（AD/PD(TM) 2022）において発表 Eisai Mar 22, 2022 13:00 JST Read More
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting Eisai Mar 22, 2022 09:21 HKT/SGT Read More
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen Eisai Mar 15, 2022 12:03 HKT/SGT Read More
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments Eisai Mar 15, 2022 11:00 HKT/SGT Read More
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting Eisai Mar 11, 2022 11:15 HKT/SGT Read More
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) Eisai Mar 09, 2022 15:06 HKT/SGT Read More
NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets NEC Corporation Mar 09, 2022 08:05 HKT/SGT Read More
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma Eisai Mar 07, 2022 12:50 HKT/SGT Read More
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 Eisai Mar 07, 2022 11:50 JST Read More
Fujitsu and Tokyo Medical and Dental University leverage world's fastest supercomputer and AI technology for scientific discovery to shed light on drug resistance in cancer treatment Fujitsu Ltd Mar 07, 2022 09:21 HKT/SGT Read More
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始 Eisai Mar 04, 2022 12:00 JST Read More
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab Eisai Mar 04, 2022 10:05 HKT/SGT Read More
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics Oculis S.A. Mar 02, 2022 20:47 HKT/SGT Read More
